Saccharomyces Cerevisiae for Irritable Bowel Syndrome

Efficacy and Safety of Saccharomyces Cerevisiae for Abdominal Pain and Discomfort in Irritable Bowel Syndrome (IBS) Patients

This study is designed to see the response of saccharomyces cerevisiae for symptomatic improvement of patients with IBS

Inclusion Criteria:

• Male and female patients between 18 and 75 years of age,
• Patients having confirmed IBS according to Rome IV criteria (newly and previously non-responder to treatment),
• Pain/ discomfort score strictly above 1 and strictly below 6 as determined on a pain/ discomfort scale using arbitrary grading from 0 to 7 in 7 days preceding the inclusion visit,
• Not hypersensitive to any of the ingredients of the drug.

Exclusion Criteria:

• Patients with an organic intestinal disease (Crohn's disease, ulcerative colitis, etc.),
• Pregnant females
• Treatments likely to influence IBS (anti-depressants, opioids, and narcotic analgesics)
• Patients with chronic alcoholism, vegetarian or vegan regimens
• Eating disorders such as anorexia or bulimia
• Documented food allergies.